HIV VB: ‘Exceptionally’ virulent variant discovered in the Netherlands

Referred to as ‘VB’, variant causes a quicker decline in protective T cells within infected patients but remains susceptible to current antiviral treatments

<p>The variant, which is thought to have arisen in the late 1990s, has infected 109 people in the country</p>

The variant, which is thought to have arisen in the late 1990s, has infected 109 people in the country

An “exceptionally” virulent variant of HIV has been detected in the Netherlands, where it has been circulating for several years, scientists say.

The variant, which is thought to have arisen in the late 1990s, has infected 109 people in the country, according to an article published in Science.

Without treatment, the variant – referred to as VB – appears capable of accelerating patients’ usual progression to advanced HIV and AIDS-related complications.

This is because it causes a decline in protective T cells twice as quick as other variants, the scientists said.

By the time of their diagnosis, the 109 individuals with VB were vulnerable to developing AIDS within two to three years, compared to six to seven for people infected with other HIV variants, the research said.

Those infected with VB also developed higher viral loads faster, suggesting it may be more effective at transmitting than other variants.

However, Professor Jonathan Stoye, a virologist at the Francis Crick Institute, said the variant “doesn’t seem to have spread very widely or infected more people than we’d typically see with other variants”.

He added: “There are always trade-offs between the speed of virus replication and transmissibility. It has to be able to replicate to high levels to transmit, but it doesn't necessarily mean it's going to predominate.

“There aren't any rules or we don't know the rules that will tell us whether a given virus with a given set of properties will actually succeed in the evolution game. Whether it will grow and out-compete other variants, we don’t know.”

People infected with VB were present in all regions of the Netherlands, but with a different distribution relative to that of non-VB individuals, the paper said. VB individuals were more prevalent in the south and less common in Amsterdam.

Despite VB’s increased virulence, it remains vulnerable to current drugs, the researchers said. After receiving treatment, those infected with VB showed similar CD4 counts as people infected with other variants.

CD4, a type of T cell responsible for protecting the body against opportunistic infections, are targeted and attacked by HIV. Antiviral medicine helps to prevent HIV replication and restore the level of CD4 cells in an infected person, meaning they are no longer able to pass on the virus and can live a normal life.

“Had VB individuals not started treatment earlier than others, lower CD4 counts at treatment initiation would have been expected, potentially causing increased morbidity and mortality,” the researchers said.

Researchers assessed VB samples stretching back to one patient who was diagnosed with HIV in 1992. However, it wasn’t until 10 years later that the variant started appearing in other individuals.

Prof Stoye said it was unclear from the research why VB appears to be more effective at replicating than other HIV variants. “I’d like to know why all the changes that have occurred in this virus causes it to grow better, but there's that there's no clue to that question.”

There are more than 750 mutations in VB compared to other HIV variants in circulation in the Netherlands, the paper said.

Give the ability of VB to rapidly replicate in infected people and progress to advanced HIV, the variant is of “concern”, the scientists said.

“Without treatment, advanced HIV is expected to be reached in only nine months from the time of diagnosis for VB individuals, compared with 36 months for non-VB individuals, in males diagnosed at the age of 30 to 39 years,” they wrote.

“In contexts with less awareness and monitoring, in which diagnosis often occurs later in infection, the probability of reaching advanced HIV before diagnosis would be even greater.”

Prof Stoye said VB “might be more serious” in countries where there is “less early diagnosis” and limited access to antiviral treatments, pointing to South Africa. “But I don’t think we can predict whether it will come to in any way spread through these types of populations.”

Referencing coronavirus, Prof Stoye said that VB was proof that viruses don’t always evolve to become more mild. “There's been this widespread view that coronavirus will just get more and more mild but I don't think that's true.

“Viruses can go up in terms of virulence, or down.”

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in